MPN Hub summary Impact of mutated JAK2 allele burden on the outcomes in PV and ET of a recent article by Guglielmelli et al.
durable molecular response (DMR)
complete clinical and hematological response (CCHR)
"Increased DMR was correlated with longer duration of CCHR, reduced progression to myelofibrosis, and increased rates of myelofibrosis-free, event-free, and progression-free survival.
Factors predicting DMR and reduced progression to myelofibrosis included a baseline JAK2 VAF <50% and a VAF reduction ≥35% after 2 years of treatment.
The findings underscore the significance of targeted molecular response in managing myeloproliferative neoplasms, advocating for personalized treatment strategies based on JAK2 VAF dynamics." mpn-hub.com/medical-informa...
Directly from the Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia article abstract.
molecular response (MR)
"Overall, these findings support the clinical value of achieving profound, durable MR and its consideration as surrogate endpoint in future clinical trials." onlinelibrary.wiley.com/doi...
Very interesting and relevant finding.
MPN Mutant Cell Fitness vs VAF
Ropeg versus HU/BAT results after 3 years
